{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:43:14Z","timestamp":1793889794296,"version":"4.8.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"\n Importance<\/jats:title>\n Triptans are contraindicated in patients with ischemic heart disease or previous myocardial infarction, and caution is advised when prescribing these drugs to patients with vascular risk factors. However, controlled observational studies have either shown no association or an apparent lower risk, possibly owing to a channeling of triptans to individuals at low risk of cardiovascular outcomes, and it remains unclear whether avoiding triptan treatment for these patients is meaningful.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To establish whether an association between triptans and ischemic events could be demonstrated using a self-controlled design because this type of design is robust to the previously mentioned type of confounding.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n All people in nationwide Danish registries who were initiating triptans and all the ischemic events that they experienced were identified. A case-crossover design was used to estimate odds ratios (OR) for associations between first-ever triptan use and ischemic outcomes, comparing triptan exposure in the 2-week period up to the event with four 2-week reference periods. Data were obtained for the period January 1995 to August 2022. Included from the population of Denmark were individuals redeeming a prescription for any triptan and experiencing at least 1 of 3 predefined ischemic outcomes. No one was excluded.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Initiation of any triptan.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Acute myocardial infarction, ischemic stroke, or nonspecified stroke.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Identified were a total of 429\u202f612 individuals (median [IQR] age, 38 [28-48] years; 325\u202f687 female [75.8%]) who redeemed a first prescription for a triptan in the study period. Of these patients, 11 (0.003%) had a myocardial infarction with the first triptan prescription in either a focal or referent window (odds ratio [OR], 3.3; 95% CI, 1.0-10.9), 18 (0.004%) had ischemic stroke (OR, 3.2; 95% CI, 1.3-8.1), and 35 (0.008%) had ischemic\/nonspecified stroke (OR, 3.0; 95% CI, 1.5-5.9). Case patients had a median age of approximately 60 years and had a high-risk cardiovascular profile.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Results of this case-crossover study suggest that triptan initiation was associated with higher risk of ischemic stroke and myocardial infarction. For the individual patient with low background cardiovascular risk, the risk of an ischemic event after triptan initiation was very low.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2023.5549","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T11:01:11Z","timestamp":1707130871000},"page":"248","source":"Crossref","is-referenced-by-count":51,"title":["Risk of Stroke and Myocardial Infarction Among Initiators of Triptans"],"prefix":"10.1001","volume":"81","author":[{"given":"Christian Lund","family":"Petersen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark"},{"name":"Department of Radiology, University Hospital of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hougaard","sequence":"additional","affiliation":[{"name":"Department of Neurology, Copenhagen University Hospital\u2014Herlev, Herlev, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gaist","sequence":"additional","affiliation":[{"name":"Research Unit for Neurology, Odense University Hospital, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark"},{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"noi230101r1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/14656566.2020.1828347","article-title":"Pharmacological strategies to treat attacks of episodic migraine in adults.","volume":"22","author":"Tfelt-Hansen","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"noi230101r2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","article-title":"Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?","volume":"186","author":"Rubio-Beltr\u00e1n","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"16","key":"noi230101r3","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1517\/14656566.2010.522567","article-title":"Sumatriptan therapy for headache and acute myocardial infarction.","volume":"11","author":"Barra","year":"2010","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"noi230101r4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1046\/j.1468-2982.2000.00116.x","article-title":"Tolerability of sumatriptan: clinical trials and postmarketing experience.","volume":"20","author":"Welch","year":"2000","journal-title":"Cephalalgia"},{"issue":"6","key":"noi230101r5","first-page":"541","article-title":"The effect of IV sumatriptan, a selective 5-HT1-receptor agonist, on central haemodynamics and the coronary circulation.","volume":"34","author":"Macintyre","year":"1992","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"noi230101r6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1161\/01.CIR.87.2.401","article-title":"Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation.","volume":"87","author":"MacIntyre","year":"1993","journal-title":"Circulation"},{"issue":"5","key":"noi230101r7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.5811\/westjem.2015.6.25920","article-title":"ST-elevation myocardial infarction after sumitriptan ingestion in patient with normal coronary arteries.","volume":"16","author":"Jensen","year":"2015","journal-title":"West J Emerg Med"},{"issue":"5","key":"noi230101r8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/hed.2009.49.issue-5","article-title":"Acute myocardial infarction with sumatriptan: a case report and review of the literature.","volume":"49","author":"Chalaupka","year":"2009","journal-title":"Headache"},{"issue":"8","key":"noi230101r9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-235387","article-title":"Vasospasm induced myocardial ischaemia secondary to sumatriptan use.","volume":"13","author":"Okonkwo","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"11","key":"noi230101r10","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.amjmed.2006.03.047","article-title":"Myocardial infarction after oral sumatriptan use in a woman with normal coronary arteries.","volume":"120","author":"Weir","year":"2007","journal-title":"Am J Med"},{"issue":"4","key":"noi230101r11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s00246-004-0768-4","article-title":"A case of myocardial infarction with sumatriptan use.","volume":"26","author":"Erbilen","year":"2005","journal-title":"Pediatr Cardiol"},{"issue":"10127","key":"noi230101r12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","article-title":"Migraine.","volume":"391","author":"Dodick","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"noi230101r15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S1474-4422(13)70067-X","article-title":"Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study.","volume":"12","author":"Amin","year":"2013","journal-title":"Lancet Neurol"},{"issue":"10","key":"noi230101r16","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/hed.2007.47.issue-10","article-title":"Migraine and the risk of stroke, TIA, or death in the UK (CME).","volume":"47","author":"Becker","year":"2007","journal-title":"Headache"},{"key":"noi230101r17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ebiom.2016.02.039","article-title":"Risk of stroke in migraineurs using triptans. associations with age, sex, stroke severity and subtype.","volume":"6","author":"Albieri","year":"2016","journal-title":"EBioMedicine"},{"issue":"4","key":"noi230101r18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1212\/01.WNL.0000110312.36809.7F","article-title":"Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice.","volume":"62","author":"Hall","year":"2004","journal-title":"Neurology"},{"issue":"2","key":"noi230101r19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/hed.2010.50.issue-2","article-title":"Triptan use as a function of cardiovascular risk. A population-based study.","volume":"50","author":"Bigal","year":"2010","journal-title":"Headache"},{"issue":"7","key":"noi230101r20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/hed.2004.44.issue-7","article-title":"Severe vascular events in migraine patients.","volume":"44","author":"Velentgas","year":"2004","journal-title":"Headache"},{"issue":"2","key":"noi230101r21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/oxfordjournals.aje.a115853","article-title":"The case-crossover design: a method for studying transient effects on the risk of acute events.","volume":"133","author":"Maclure","year":"1991","journal-title":"Am J Epidemiol"},{"issue":"6","key":"noi230101r22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/pds.v30.6","article-title":"Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology.","volume":"30","author":"Cadarette","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"noi230101r23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/oxfordjournals.aje.a117550","article-title":"Control sampling strategies for case-crossover studies: an assessment of relative efficiency.","volume":"142","author":"Mittleman","year":"1995","journal-title":"Am J Epidemiol"},{"issue":"1","key":"noi230101r24","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12874-021-01408-5","article-title":"A novel weighting method to remove bias from within-subject exposure dependency in case-crossover studies.","volume":"21","author":"Kubota","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"noi230101r25","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1111\/head.v60.10","article-title":"Risk of acute myocardial infarction, heart failure, and death in migraine patients treated with triptans.","volume":"60","author":"Ghanshani","year":"2020","journal-title":"Headache"},{"issue":"2","key":"noi230101r26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/0333102414550416","article-title":"Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies.","volume":"35","author":"Roberto","year":"2015","journal-title":"Cephalalgia"},{"issue":"15","key":"noi230101r27","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1212\/WNL.0000000000003814","article-title":"ED misdiagnosis of cerebrovascular events in the era of modern neuroimaging: a meta-analysis.","volume":"88","author":"Tarnutzer","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"noi230101r28","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/head.v62.9","article-title":"Short-term stroke risk after emergency department treat-and-release headache visit.","volume":"62","author":"Liberman","year":"2022","journal-title":"Headache"},{"issue":"8","key":"noi230101r29","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/j.1468-2982.2008.01590.x","article-title":"Cardiac cephalalgia: case reports and review.","volume":"28","author":"Wei","year":"2008","journal-title":"Cephalalgia"},{"key":"noi230101r13","unstructured":"Danish Medicines Agency. Sumatriptan accord. Accessed February 22, 2023. https:\/\/www.produktresume.dk\/AppBuilder\/search?q=%22Sumatriptan+Accord%2C+filmovertrukne+tabletter+50+mg+og+100+mg.docx%22"},{"key":"noi230101r14","unstructured":"US Food and Drug Administration. Sumatriptan succinate product information. Accessed March 27, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020132s028,020626s025lbl.pdf"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2814687\/jamaneurology_petersen_2024_oi_230101_1709917430.41069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T11:02:58Z","timestamp":1710154978000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2814687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2023.5549","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}